We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Portable Device Being Developed to Detect Zika at POC

By LabMedica International staff writers
Posted on 10 Mar 2017
A handheld diagnostic device may enable detection of Zika virus accurately, rapidly, and inexpensively in many settings, even at airports as it requires only a saliva sample.

Researchers from Florida Atlantic University have been developing a diagnostic tool to reduce the impact of the Zika outbreak until a vaccine is developed. More...
“Most of the Zika cases in the United States and especially in Florida are travel related,” said Waseem Asghar, PhD, lead investigator and assistant professor at FAU, “We are working to develop a tool that can be used without expensive laboratory equipment and skilled technicians […]. For about USD 2 and within 15 minutes, we hope to accurately determine whether or not an individual has an active infection.”

Currently, patients are often diagnosed by testing blood samples for antibodies against Zika virus, however, due to cross-reaction problems the antibody test does not discriminate accurately between the Zika virus and other flaviviruses such as Dengue, West Nile virus, and Chikungunya. The more accurate method of PCR detection of viral DNA is costly, requires skilled laboratory personnel, and can take hours to yield results.

This new device is based on technology that Prof. Asghar and colleagues initially developed to detect HIV. It uses inexpensive paper- or plastic-based materials, a cassette-sized container holding up to 12 samples at a time, and a receptacle about the size of a tablet. These materials are easy to make and use, and can easily and safely be disposed of by burning, providing an appealing strategy developing, low- and middle-income countries where there is limited laboratory infrastructure.

They are currently adapting their device to diagnose the Zika virus.


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Rapid Sepsis Test
SeptiCyte RAPID
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.